Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Bottaro Website

Donald P. Bottaro, Ph.D.

Selected Publications

1)  Miki T, Fleming TP, Bottaro DP, Rubin JS, Ron D, Aaronson SA.
Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop.
Science. 251: 72-5, 1991.
[Journal]
2)  Rubin JS, Chan AM, Bottaro DP, Burgess WH, Taylor WG, Cech AC, Hirschfield DW, Wong J, Miki T, Finch PW.
A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor.
Proc. Natl. Acad. Sci. U.S.A. 88: 415-9, 1991.
[Journal]
3)  Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA.
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
Science. 251: 802-4, 1991.
[Journal]
4)  Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH.
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
Science. 267: 381-3, 1995.
[Journal]
5)  Cecchi F, Pajalunga D, Fowler CA, Uren A, Rabe DC, Peruzzi B, Macdonald NJ, Blackman DK, Stahl SJ, Byrd RA, Bottaro DP.
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling.
Cancer Cell. 22: 250-62, 2012.
[Journal]
6)  Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J.
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue.
PLoS ONE. 9: e100586, 2014.
[Journal]
7)  Zhang M, Luo Z, Liu H, Croce CM, Burke TR, Bottaro DP.
Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist.
Leukemia. 28: 948-51, 2014.
[Journal]
8)  Lee YH, Morrison BL, Bottaro DP.
Synergistic Signaling of Tumor Cell Invasiveness by Hepatocyte Growth Factor and Hypoxia.
J. Biol. Chem. [Epub ahead of print], 2014.
[Journal]
9)  Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
J. Clin. Oncol. 31: 181-6, 2013.
[Journal]
10)  Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS ONE. 8: e54014, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 7/11/2014.